Management of Thyroid Storm Coagulopathy

Initial Assessment and Stabilization

Immediately hospitalize all patients with thyroid storm, with severe cases requiring ICU admission, according to Praxis Medical Insights 1
Monitor coagulation parameters including prothrombin time (PT), activated partial thromboplastin time (aPTT), Clauss fibrinogen, and if available, thromboelastography (TEG) or thromboelastometry (ROTEM), as recommended by Anaesthesia 2
Establish large-bore IV access for fluid resuscitation and medication administration, as suggested by Anaesthesia 2

Administer propylthiouracil as first choice to inhibit both thyroid hormone synthesis and peripheral T4 to T3 conversion, according to Praxis Medical Insights 3 1
Administer saturated potassium iodide solution or sodium iodide 1-2 hours after starting thionamides to block thyroid hormone release, as recommended by Praxis Medical Insights 3 1
Control adrenergic symptoms with beta-blockers, preferably propranolol at 60-80 mg orally every 4-6 hours, according to Praxis Medical Insights 3
Administer dexamethasone or another corticosteroid to reduce peripheral conversion of T4 to T3 and treat potential relative adrenal insufficiency, as suggested by Praxis Medical Insights 3 1

Consider temporary inferior vena cava filtration in patients with extensive lower extremity thrombosis who cannot receive anticoagulation, as recommended by Anaesthesia 2
Provide blood component therapy as needed, including fresh frozen plasma, platelets, and cryoprecipitate, according to Anaesthesia 2

Increase frequency of observations for patients with thyroid storm and coagulopathy, as suggested by Praxis Medical Insights 1
Watch for cardiac complications such as heart failure, according to Praxis Medical Insights 1
Monitor thyroid function every 2-3 weeks after initial stabilization, as recommended by Praxis Medical Insights 3
Standard venous thromboprophylaxis should be continued after the acute crisis until the patient is euthyroid, according to Anaesthesia 2

For pregnant patients, the treatment protocol is similar to non-pregnant patients, with monitoring of fetal status, as recommended by Praxis Medical Insights 3 1
Monitor for development of agranulocytosis with thionamide use, according to Praxis Medical Insights 1
Watch for transition to hypothyroidism after thyroid storm treatment, as suggested by Praxis Medical Insights 3

Do not delay treatment of thyroid storm while awaiting laboratory confirmation, as mortality rises significantly with treatment delays, according to Praxis Medical Insights 1
Never administer iodine before thionamides, as this can worsen thyrotoxicosis, as recommended by Praxis Medical Insights 3 1

Thionamide therapy (propylthiouracil or methimazole) can cause a rare but potentially fatal combination of agranulocytosis and thrombocytopenia, representing the most likely etiology of severe hematologic derangement in patients experiencing a thyroid storm. 4
Agranulocytosis develops in approximately 0.2 %–0.5 % of individuals receiving thionamides, usually within the first 3 months of treatment; thrombocytopenia is a recognized concurrent hematologic adverse effect. 4

Mild thrombocytopenia may be observed in hyperthyroid states due to reduced platelet survival, but when it co‑exists with agranulocytosis it strongly suggests drug‑induced pancytopenia rather than a direct effect of thyroid disease. [5][6]